Major Research Shows Oridion Capnography Monitoring Significantly Improves Patient Safety during Gastrointestinal Endoscopy

Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that an extensive medical research study conducted at the Cleveland Clinic Foundation on the value of continuous Microstream® capnography monitoring in improving patient safety during procedural sedation was published in the May issue of Gastroenterology. The article has also been highlighted as the Editor's Essential Reading on the website of Gastroenterology - the official journal of the AGA (American Gastroenterological Association) Institute.

Jerusalem/Needham (PRWEB) May 27, 2009

Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that an extensive medical research study conducted at the Cleveland Clinic Foundation on the value of continuous Microstream® capnography monitoring in improving patient safety during procedural sedation was published in the May issue of Gastroenterology. The article has also been highlighted as the Editor's Essential Reading on the website of Gastroenterology - the official journal of the AGA (American Gastroenterological Association) Institute.

Oridion provides monitoring solutions that enable the clinician to simply and accurately assess a patient's ventilatory status. By enabling the earliest detection of a respiratory event, and immediate feedback on the efficacy of treatment, Oridion Microstream capnography improves patient safety and patient outcomes. A short summary of this published study is described below.

This research study confirms the clinical benefits of continuous waveform CO2 monitoring using Oridion Microstream® capnography to reduce the incidence of hypoxemia, severe hypoxemia, and apnea in procedural sedation. These benefits persisted even after oxygen supplementation.
The aim of the study was to examine whether intervention, based on information from capnography monitoring of patients under sedation for gastrointestinal endoscopy procedures, could reduce the frequency of hypoxemia and apnea. The study analyzed a total of 247 patients undergoing ERCP and EUS procedures in a randomized, double blinded design using the Oridion Smart CapnoBloc™ ventilation management system (CO2 sampling incorporated into a bite block) and the Capnostream™20 dual parameter monitor.

Results demonstrated that capnographic monitoring of respiratory activity significantly reduced the frequency of hypoxemia, severe hypoxemia, and apnea. The benefit of capnography persisted even after oxygen supplementation.

The authors concluded that capnography monitoring functions as an early warning system for hypoxemia and may further improve patient safety during gastrointestinal endoscopy.
Dr. John Vargo MD, MPH and Mohammed Qadeer MD, MPH from the Digestive Disease Institute at the Cleveland Clinic Foundation, Cleveland, Ohio, were the lead clinical investigators on the research project. "This is the first data in the endoscopic literature to show a benefit for capnographic monitoring in patients undergoing prolonged endoscopic procedures such as ERCP and EUS" Vargo said.    "The study also confirmed some of our previous observations that significant alterations in ventilation can occur without oxygen desaturation. In fact, capnographic abnormalities frequently precede the development of hypoxemia."

Oridion is the global market leader in capnography monitoring and its innovative solutions help to improve patient safety and patient outcomes. Oridion Microstream technology is the standard of care in ventilation monitoring.

For further Oridion information please contact
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations

website: http://www.oridion.com
phone: +972 2 589 9159
address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

About Oridion
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

The Company does not assure any obligation to update the forward looking information contained in this press release.

###